HLN
HealthcareHaleon plc · Drug Manufacturers - Specialty & Generic · $41B
What is Haleon plc?
Haleon plc is a large-cap consumer healthcare company headquartered in Weybridge, United Kingdom. It sells trusted over-the-counter health brands across more than 100 markets worldwide, spanning oral care, pain relief, and vitamins.
Haleon develops, manufactures, and markets consumer healthcare products across several therapeutic categories. The company generates revenue by selling branded over-the-counter products directly to consumers through pharmacies, retailers, and e-commerce channels. Its business model relies on brand recognition and repeat purchasing in categories such as oral health, pain relief, respiratory health, digestive health, and vitamins and supplements. Operations span North America, Europe, the Middle East, Africa, Latin America, and Asia Pacific.
Haleon was incorporated in 2021 and officially launched as an independent company in 2022, with its headquarters in Weybridge, UK.
- Oral health products including Sensodyne, Polident, and parodontax
- Pain relief brands such as Panadol, Advil, and Voltaren
- Respiratory health products including Otrivin and Theraflu
- Digestive health solutions for everyday consumer needs
- Vitamins, minerals, and supplements under the Centrum brand
Is HLN a Good Stock to Buy?
UQS Score rates HLN as Below Average overall, reflecting meaningful challenges across several key investment pillars.
Among the five pillars, Quality and Valuation both register as Neutral — suggesting the business maintains a functional operating structure and is not dramatically mispriced relative to its fundamentals. The company's portfolio of globally recognized consumer brands provides some stability in revenue generation.
Moat, Growth, and Risk all score as Weak, indicating limited competitive differentiation, subdued expansion prospects, and elevated financial or operational vulnerabilities that investors should weigh carefully.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does HLN pay dividends?
Yes — Haleon plc pays a dividend.
Haleon pays a regular dividend, which is consistent with its positioning as a mature consumer healthcare company with predictable cash flows from established brands. Income-oriented investors may find this appealing, though the sustainability of the dividend should be evaluated alongside the company's Weak Risk pillar rating. For current yield and payout details, refer to Haleon's investor relations page.
When does HLN report earnings?
Haleon reports earnings on a regular cadence, consistent with standard practice for internationally listed companies of its size.
Haleon's recent results reflect the dynamics of a consumer healthcare business navigating cost pressures and competitive markets. Revenue trends across its core categories have been mixed, consistent with the Weak Growth pillar rating assigned by UQS.
For the most recent quarter's results and guidance, visit Haleon's official investor relations page.
HLN Price History
+43.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Haleon plc?
Based on Haleon plc's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
HLN Long-term Outlook
Haleon's fundamental outlook is shaped by its Weak Growth and Weak Risk pillar ratings. The company faces headwinds in expanding its top line meaningfully while managing a balance sheet that carries notable leverage from its 2022 separation. Neutral Valuation suggests the market has already priced in much of the uncertainty, leaving limited upside unless operational improvements materialize. Progress in reducing debt and reinvigorating brand investment will be key factors to watch.
Growth drivers
- Expansion of established brands into underpenetrated emerging markets
- Consumer demand for trusted over-the-counter health products post-pandemic
- Portfolio optimization and potential bolt-on additions in high-growth categories
Key risks
- Elevated debt load from the 2022 corporate separation weighing on financial flexibility
- Weak competitive moat leaving brands exposed to private-label and generic competition
- Subdued organic growth in mature markets limiting revenue acceleration
HLN vs Peers
Haleon operates in a competitive consumer and pharmaceutical healthcare landscape alongside companies with distinct business models and risk profiles.
Teva focuses primarily on generic and specialty pharmaceuticals rather than consumer-facing branded health products, giving it a different revenue and margin structure.
Zoetis concentrates exclusively on animal health medicines and vaccines, serving a distinct end market compared to Haleon's human consumer healthcare focus.
Takeda is a global prescription pharmaceutical company with a strong oncology and rare disease pipeline, contrasting with Haleon's over-the-counter consumer model.
Frequently Asked Questions
What does Haleon do?
Haleon is a consumer healthcare company that develops and sells over-the-counter health products globally. Its portfolio covers oral health, pain relief, respiratory health, digestive health, and vitamins and supplements, with brands like Sensodyne, Panadol, Advil, and Centrum sold across more than 100 countries.
Does HLN pay dividends?
Yes, Haleon pays a regular dividend. This reflects the company's mature business model and relatively predictable cash flows from its established brand portfolio. Investors should review the current yield and payout ratio on Haleon's investor relations page, particularly given the Weak Risk pillar rating.
When does HLN report earnings?
Haleon reports financial results on a regular cadence in line with standard practice for large-cap internationally listed companies. For confirmed upcoming reporting dates, check Haleon's official investor relations page or your brokerage's earnings calendar.
Is HLN a good stock to buy?
UQS Score rates HLN as Below Average, driven by Weak scores across Moat, Growth, and Risk pillars. Quality and Valuation are Neutral. This profile suggests the stock carries meaningful challenges that investors should weigh carefully before committing capital. The complete analysis is available to UQS Pro members.
Is HLN overvalued?
HLN's Valuation pillar is rated Neutral by UQS, suggesting the stock is neither clearly cheap nor obviously expensive relative to its fundamentals. Given the Weak Growth and Risk ratings, investors should consider whether the current price adequately compensates for the underlying business challenges.
How does HLN compare to its competitors?
Compared to peers like Teva, Zoetis, and Takeda, Haleon is distinctive in its pure focus on branded consumer over-the-counter health products. Unlike prescription-focused pharmaceutical peers, Haleon's revenue depends heavily on consumer brand loyalty and retail distribution rather than clinical pipelines or generic drug volumes.
What is HLN's market cap bracket?
Haleon is classified as a large-cap company, reflecting its significant global scale across consumer healthcare categories. Large-cap stocks like HLN typically offer greater liquidity and more analyst coverage than smaller peers, though size alone does not determine investment quality.
Who founded Haleon?
Haleon was formed through the combination of consumer healthcare businesses from GlaxoSmithKline and Pfizer, before being spun off as an independent publicly listed company in 2022. Information on its leadership and corporate history is available on Haleon's official website.
Is HLN a long-term quality investment?
As a long-term quality indicator, UQS rates HLN as Below Average. The Weak Moat and Weak Growth pillars suggest the business may struggle to compound value over time at a rate that outpaces peers. Neutral Quality and Valuation provide some floor, but long-term investors should monitor debt reduction and brand investment trends closely.
What is the main competitive advantage of Haleon?
Haleon's primary advantage lies in its portfolio of globally recognized consumer health brands — including Sensodyne, Panadol, and Centrum — which benefit from consumer trust and repeat purchasing behavior. However, UQS rates the Moat pillar as Weak, indicating this advantage may not be sufficiently durable to fend off private-label and generic competition.
What sector does HLN belong to?
Haleon operates in the Healthcare sector, specifically within consumer healthcare — a segment that sits at the intersection of consumer staples and healthcare. This positioning gives the company relatively defensive revenue characteristics, though it also limits the high-growth potential seen in pharmaceutical or biotech peers.
Unlock Full HLN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact scores across all five UQS pillars
- ✓Access full financial metrics and trend data
- ✓Compare HLN against sector peers side by side
- ✓See the complete risk and valuation breakdown
- ✓Get alerts when HLN's UQS Score changes
Pro Analysis
HLN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 41.1 | 43.1 | 29.0 | 40.4 | 39.3 | 60.5 | +2.0 |
| May 10, 2026 | 39.1 | 24.9 | 29.0 | 40.4 | 47.3 | 69.5 | +0.1 |
| May 8, 2026 | 39.0 | 24.9 | 29.0 | 40.4 | 47.3 | 68.7 | -2.0 |
| May 7, 2026 | 41.0 | 42.8 | 29.0 | 40.5 | 39.3 | 60.0 | -0.1 |
| May 5, 2026 | 41.1 | 42.8 | 29.0 | 40.5 | 39.3 | 60.7 | +0.4 |
| May 3, 2026 | 40.7 | 42.8 | 29.0 | 39.2 | 39.3 | 60.3 | +0.1 |
| May 1, 2026 | 40.6 | 42.8 | 29.0 | 39.2 | 39.3 | 59.6 | +0.1 |
| Apr 26, 2026 | 40.5 | 42.8 | 29.0 | 38.7 | 39.3 | 59.5 | +0.1 |
| Apr 25, 2026 | 40.4 | 42.8 | 29.0 | 38.7 | 39.3 | 58.9 | -0.1 |
| Apr 23, 2026 | 40.5 | 42.8 | 29.0 | 38.7 | 39.3 | 59.2 | -0.1 |
HLN — Pillar Breakdown
Quality
— 43.1/100 (25%)Haleon plc has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 40.4/100 (20%)Haleon plc shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 39.3/100 (15%)Haleon plc has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 60.2/100 (15%)Haleon plc trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 29/100 (25%)Haleon plc operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for HLN.
Score Composition
Financial Data
More Stock Analysis
How is the HLN UQS Score Calculated?
The UQS (Unified Quality Score) for Haleon plc is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Haleon plc's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Haleon plc is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.